Bruce Lipschutz, DO
Internal Medicine · Fort Myers, FLNPI 1225038706
Payments from drug & device makers
Across 428 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$790
- GSK$751
- Amgen$730
- AbbVie$661
- Lilly USA, LLC$484
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,72899%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $1,007 |
| AstraZeneca | 37 | $790 |
| GSK | 55 | $751 |
| Amgen(2 entities) | 43 | $730 |
| AbbVie(2 entities) | 35 | $661 |
| Lilly USA, LLC | 27 | $484 |
| Pfizer | 23 | $410 |
| Mannkind Corporation | 20 | $323 |
| Abbott | 10 | $301 |
| Johnson & Johnson | 9 | $296 |
| Merck | 12 | $288 |
| Bayer | 9 | $269 |
| Amarin Pharma, Inc. | 10 | $238 |
| Teva Pharmaceuticals USA, Inc. | 15 | $225 |
| Novartis | 10 | $150 |
| Arbor Pharmaceuticals, Inc. | 8 | $140 |
| Dexcom, Inc. | 8 | $131 |
| Boston Scientific | 2 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Astellas Pharma US Inc | 3 | $54 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Antares Pharma, Inc. | 3 | $48 |
| Biohaven Pharmaceuticals, Inc. | 3 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Halozyme Inc | 1 | $26 |
| Boehringer Ingelheim | 2 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Optinose US, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,776 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 214 | $242,847 |
| FarxigaDapagliflozin Propanediol | 131 | $154,711 |
| EliquisApixaban | 103 | $119,011 |
| RybelsusSemaglutide | 62 | $87,570 |
| JardianceEmpagliflozin | 61 | $76,901 |
| XareltoRivaroxaban | 30 | $41,669 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $36,335 |
| VascepaIcosapent Ethyl | 44 | $35,709 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $34,075 |
| Repatha SureclickEvolocumab | 38 | $33,047 |
| TrulicityDulaglutide | 26 | $24,358 |
| MyrbetriqMirabegron | 17 | $22,129 |
| GemtesaVibegron | 20 | $22,005 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $20,688 |
| MounjaroTirzepatide | 17 | $18,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,007 | $330,417276 claims |
| AstraZenecaFarxiga | $790 | $154,711131 claims |
| PfizerEliquis | $410 | $119,011103 claims |
| Boehringer IngelheimJardiance | $25 | $76,90161 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $751 | $72,00586 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $484 | $43,04043 claims |
| Johnson & JohnsonXarelto | $296 | $41,66930 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $22,12917 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $38 | $22,00520 claims |
| AbbVieSynthroid | $661 | $2,52533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Fort Myers
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.